Therapeutic classes that prevent ventricular remodelling (such as angiotensin-converting enzyme inhibitors and mineralocorticoid receptor antagonists) are indicated in subjects with ACS and CKD (who also have predictors of ventricular remodelling). The gene discussed is ACE; the disease is chronic kidney disease.